These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20213024)

  • 41. What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose.
    Yan SD; Stern D; Schmidt AM
    Eur J Clin Invest; 1997 Mar; 27(3):179-81. PubMed ID: 9088851
    [No Abstract]   [Full Text] [Related]  

  • 42. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
    Lue LF; Yan SD; Stern DM; Walker DG
    Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):249-66. PubMed ID: 15975028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential effects between amphoterin and advanced glycation end products on colon cancer cells.
    Kuniyasu H; Chihara Y; Kondo H
    Int J Cancer; 2003 May; 104(6):722-7. PubMed ID: 12640679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways.
    Huttunen HJ; Fages C; Rauvala H
    J Biol Chem; 1999 Jul; 274(28):19919-24. PubMed ID: 10391939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging.
    Yan SF; D'Agati V; Schmidt AM; Ramasamy R
    Curr Mol Med; 2007 Dec; 7(8):699-710. PubMed ID: 18331228
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular disease: what's all the AGE/RAGE about?
    Barlovic DP; Thomas MC; Jandeleit-Dahm K
    Cardiovasc Hematol Disord Drug Targets; 2010 Mar; 10(1):7-15. PubMed ID: 20041839
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line.
    Choi J; Lee MK; Oh KH; Kim YS; Choi HY; Baek SK; Jung KY; Woo JS; Lee SH; Kwon SY
    Tumori; 2011; 97(2):196-202. PubMed ID: 21617715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease.
    Schmidt AM; Stern DM
    Front Biosci; 2001 Oct; 6():D1151-60. PubMed ID: 11578972
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation.
    Huttunen HJ; Kuja-Panula J; Rauvala H
    J Biol Chem; 2002 Oct; 277(41):38635-46. PubMed ID: 12167613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1.
    Rai V; Maldonado AY; Burz DS; Reverdatto S; Yan SF; Schmidt AM; Shekhtman A
    J Biol Chem; 2012 Feb; 287(7):5133-44. PubMed ID: 22194616
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RAGE and TLRs: relatives, friends or neighbours?
    Ibrahim ZA; Armour CL; Phipps S; Sukkar MB
    Mol Immunol; 2013 Dec; 56(4):739-44. PubMed ID: 23954397
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Expression of high mobility group protein B1 in periodontal tissues and its association with hepatic lipid metabolism in diabetic rats with periodontitis].
    Pei X; Meng S; Gou C; Du Q
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Jan; 40(1):6-12. PubMed ID: 32376562
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation.
    Yan SF; Yan SD; Ramasamy R; Schmidt AM
    Ann Med; 2009; 41(6):408-22. PubMed ID: 19322705
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stimulation of erythroleukaemia cell differentiation by extracellular high-mobility group-box protein 1 is independent of the receptor for advanced glycation end-products.
    Sparatore B; Pedrazzi M; Passalacqua M; Gaggero D; Patrone M; Pontremoli S; Melloni E
    Biochem J; 2002 May; 363(Pt 3):529-35. PubMed ID: 11964153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis.
    Kim W; Hudson BI; Moser B; Guo J; Rong LL; Lu Y; Qu W; Lalla E; Lerner S; Chen Y; Yan SS; D'Agati V; Naka Y; Ramasamy R; Herold K; Yan SF; Schmidt AM
    Ann N Y Acad Sci; 2005 Jun; 1043():553-61. PubMed ID: 16037278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging.
    Yan SF; Ramasamy R; Schmidt AM
    Biochem Pharmacol; 2010 May; 79(10):1379-86. PubMed ID: 20096667
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glycation & the RAGE axis: targeting signal transduction through DIAPH1.
    Shekhtman A; Ramasamy R; Schmidt AM
    Expert Rev Proteomics; 2017 Feb; 14(2):147-156. PubMed ID: 27967251
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation.
    Huttunen HJ; Kuja-Panula J; Sorci G; Agneletti AL; Donato R; Rauvala H
    J Biol Chem; 2000 Dec; 275(51):40096-105. PubMed ID: 11007787
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RAGE and the pathogenesis of chronic kidney disease.
    D'Agati V; Schmidt AM
    Nat Rev Nephrol; 2010 Jun; 6(6):352-60. PubMed ID: 20421886
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.
    Yamagishi S; Nakamura K; Matsui T
    Pharmacol Res; 2009 Sep; 60(3):174-8. PubMed ID: 19646657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.